In the SURMOUNT trials for tirzepatide, researchers used an escalation starting at 2.5 mg weekly, increasing by 2.5 mg every four weeks until reaching the target maintenance dose (typically 5 mg, 10 mg, or 15 mg)
This baseline gives you a reference point for tracking improvements and catching any adverse changes early
If tirzepatide blunts your appetite more sharply, you may just have to be more intentional about drinking: thirst cues can fade along with hunger
The slower you lose the weight, the less your skin sags
Under the brand name Egrifta, Tesamorelin is FDA-approved for HIV-associated lipodystrophy
Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial